表紙
市場調査レポート

Agile Therapeutics, Inc. - 製品パイプライン分析

Agile Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 259390
出版日 ページ情報 英文 28 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
Agile Therapeutics, Inc. - 製品パイプライン分析 Agile Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年03月26日 ページ情報: 英文 28 Pages
概要

Agile Therapeutics, Inc. は、独自の特許権を有する経皮技術に基づく避妊用品を開発している製薬会社で、プロゲスチンのみの避妊パッチを提供しています。その粘着技術は安定し、信頼性の高いものです。週1回の使用で便宜性と服薬順守を両立できます。

当レポートでは、Agile Therapeutics, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Agile Therapeutics, Inc.の基本情報

Agile Therapeutics, Inc.の概要

  • 主要情報
  • 企業情報

Agile Therapeutics, Inc.:R&Dの概要

  • 主な治療範囲

Agile Therapeutics, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ

Agile Therapeutics, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Agile Therapeutics, Inc.:薬剤プロファイル

  • (ethinyl estradiol + levonorgestrel)
  • AG-200 ER
  • levonorgestrel
  • AG-200 SP

Agile Therapeutics, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Agile Therapeutics, Inc.:最近のパイプライン動向

Agile Therapeutics, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06886CDB

Summary

Global Markets Direct's, 'Agile Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Agile Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Agile Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Agile Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Agile Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Agile Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Agile Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Agile Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Agile Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Agile Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agile Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Agile Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Agile Therapeutics, Inc. Snapshot
    • Agile Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Agile Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Agile Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Agile Therapeutics, Inc. - Pipeline Products Glance
    • Agile Therapeutics, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Agile Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Agile Therapeutics, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Agile Therapeutics, Inc. - Drug Profiles
    • (ethinyl estradiol + levonorgestrel)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-200 ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levonorgestrel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-200 SP
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Agile Therapeutics, Inc. - Pipeline Analysis
    • Agile Therapeutics, Inc. - Pipeline Products by Target
    • Agile Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Agile Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Agile Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Agile Therapeutics, Inc. - Recent Pipeline Updates
  • Agile Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Agile Therapeutics, Inc., Key Information
  • Agile Therapeutics, Inc., Key Facts
  • Agile Therapeutics, Inc. - Pipeline by Indication, 2015
  • Agile Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Agile Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Agile Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Agile Therapeutics, Inc. - Phase III, 2015
  • Agile Therapeutics, Inc. - Phase II, 2015
  • Agile Therapeutics, Inc. - Phase I, 2015
  • Agile Therapeutics, Inc. - Discovery, 2015
  • Agile Therapeutics, Inc. - Pipeline by Target, 2015
  • Agile Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Agile Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Agile Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Agile Therapeutics, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Agile Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Agile Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Agile Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Agile Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Agile Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Agile Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top